Simcere Pharmaceutical Group Limited S2P.F Stock
Simcere Pharmaceutical Group Limited Price Chart
Simcere Pharmaceutical Group Limited S2P.F Financial and Trading Overview
| Simcere Pharmaceutical Group Limited stock price | 0.62 EUR |
| Previous Close | 0.9 EUR |
| Open | 0.9 EUR |
| Bid | 0.9 EUR x N/A |
| Ask | 0.91 EUR x N/A |
| Day's Range | 0.9 - 0.9 EUR |
| 52 Week Range | 0.86 - 1.56 EUR |
| Volume | 551 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 2.38B EUR |
| Beta (5Y Monthly) | 0.488965 |
| PE Ratio (TTM) | 17.9 |
| EPS (TTM) | 0.03 EUR |
| Forward Dividend & Yield | 0.02 (2.51%) |
| Ex-Dividend Date | June 28, 2022 |
| 1y Target Est | N/A |
S2P.F Valuation Measures
| Enterprise Value | 1.26B EUR |
| Trailing P/E | 17.9 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.37732053 |
| Price/Book (mrq) | 0.3340799 |
| Enterprise Value/Revenue | 0.199 |
| Enterprise Value/EBITDA | 1.537 |
Trading Information
Simcere Pharmaceutical Group Limited Stock Price History
| Beta (5Y Monthly) | 0.488965 |
| 52-Week Change | -24.35% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.56 EUR |
| 52 Week Low | 0.86 EUR |
| 50-Day Moving Average | 1 EUR |
| 200-Day Moving Average | 1.14 EUR |
S2P.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 2.66B |
| Float | 815.38M |
| Short Ratio | N/A |
| % Held by Insiders | 69.20% |
| % Held by Institutions | 5.70% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.16 |
| Trailing Annual Dividend Yield | 17.87% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.41689998 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 14.76% |
| Operating Margin (ttm) | 9.62% |
| Gross Margin | 79.07% |
| EBITDA Margin | 12.92% |
Management Effectiveness
| Return on Assets (ttm) | 3.62% |
| Return on Equity (ttm) | 13.65% |
Income Statement
| Revenue (ttm) | 6.32B EUR |
| Revenue Per Share (ttm) | 2.42 EUR |
| Quarterly Revenue Growth (yoy) | 25.69% |
| Gross Profit (ttm) | N/A |
| EBITDA | 816.56M EUR |
| Net Income Avi to Common (ttm) | 932.77M EUR |
| Diluted EPS (ttm) | 0.05 |
| Quarterly Earnings Growth (yoy) | -8.50% |
Balance Sheet
| Total Cash (mrq) | 2.62B EUR |
| Total Cash Per Share (mrq) | 0.99 EUR |
| Total Debt (mrq) | 1.51B EUR |
| Total Debt/Equity (mrq) | 21.1 EUR |
| Current Ratio (mrq) | 1.84 |
| Book Value Per Share (mrq) | 2.679 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.35B EUR |
| Levered Free Cash Flow (ttm) | 177.02M EUR |
Profile of Simcere Pharmaceutical Group Limited
| Country | Germany |
| State | N/A |
| City | Nanjing |
| Address | No. 699-18, Xuanwu Road |
| ZIP | 210042 |
| Phone | 86 25 8556 6666 |
| Website | https://www.simcere.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 7832 |
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.
Q&A For Simcere Pharmaceutical Group Limited Stock
What is a current S2P.F stock price?
Simcere Pharmaceutical Group Limited S2P.F stock price today per share is 0.62 EUR.
How to purchase Simcere Pharmaceutical Group Limited stock?
You can buy S2P.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Simcere Pharmaceutical Group Limited?
The stock symbol or ticker of Simcere Pharmaceutical Group Limited is S2P.F.
Which industry does the Simcere Pharmaceutical Group Limited company belong to?
The Simcere Pharmaceutical Group Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Simcere Pharmaceutical Group Limited have in circulation?
The max supply of Simcere Pharmaceutical Group Limited shares is 2.6B.
What is Simcere Pharmaceutical Group Limited Price to Earnings Ratio (PE Ratio)?
Simcere Pharmaceutical Group Limited PE Ratio is 20.66666800 now.
What was Simcere Pharmaceutical Group Limited earnings per share over the trailing 12 months (TTM)?
Simcere Pharmaceutical Group Limited EPS is 0.03 EUR over the trailing 12 months.
Which sector does the Simcere Pharmaceutical Group Limited company belong to?
The Simcere Pharmaceutical Group Limited sector is Healthcare.